Cargando…

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial

AIMS: Serelaxin is effective in relieving dyspnoea and improving multiple outcomes in acute heart failure (AHF). Many AHF patients have preserved ejection fraction (HFpEF). Given the lack of evidence-based therapies in this population, we evaluated the effects of serelaxin according to EF in RELAX-A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Filippatos, Gerasimos, Teerlink, John R., Farmakis, Dimitrios, Cotter, Gad, Davison, Beth A., Felker, G. Michael, Greenberg, Barry H., Hua, Tsushung, Ponikowski, Piotr, Severin, Thomas, Unemori, Elaine, Voors, Adriaan A., Metra, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	FASTTrack Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992428/ https://www.ncbi.nlm.nih.gov/pubmed/24316514 http://dx.doi.org/10.1093/eurheartj/eht497

Ejemplares similares

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
por: Metra, Marco, et al.
Publicado: (2013)

Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2017)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF
por: Liu, Licette C. Y., et al.
Publicado: (2016)

Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study
por: Metra, Marco, et al.
Publicado: (2010)

Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF
por: Voors, Adriaan A, et al.
Publicado: (2014)

Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study
por: Meyer, Sven, et al.
Publicado: (2016)

Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF
por: Davison, Beth A., et al.
Publicado: (2011)

Hepatorenal dysfunction identifies high‐risk patients with acute heart failure: insights from the RELAX‐AHF trial
por: Biegus, Jan, et al.
Publicado: (2019)

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure
por: Ponikowski, Piotr, et al.
Publicado: (2014)

Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure
por: Beldhuis, I. E., et al.
Publicado: (2023)

Relaxin, a pleiotropic vasodilator for the treatment of heart failure
por: Teichman, Sam L., et al.
Publicado: (2008)

Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction
por: van Essen, Bart J., et al.
Publicado: (2022)

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
por: Filippatos, Gerasimos, et al.
Publicado: (2016)

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
por: Pitt, Bertram, et al.
Publicado: (2013)

Vasodilators in the treatment of acute heart failure: what we know, what we don’t
por: Metra, Marco, et al.
Publicado: (2008)

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2009)

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
por: Steg, Ph. Gabriel, et al.
Publicado: (2011)

The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy
por: Gold, Michael R., et al.
Publicado: (2011)

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy
por: Tardif, Jean-Claude, et al.
Publicado: (2011)

One year follow-up of the multi-centre European PARTNER transcatheter heart valve study
por: Lefèvre, Thierry, et al.
Publicado: (2011)

Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation
por: Matsa, Elena, et al.
Publicado: (2011)

Dyssynchrony by speckle-tracking echocardiography and response to cardiac resynchronization therapy: results of the Speckle Tracking and Resynchronization (STAR) study
por: Tanaka, Hidekazu, et al.
Publicado: (2010)

Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation
por: Hjortnaes, Jesper, et al.
Publicado: (2010)

Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity® catheter system and the EnligHTN™ multi-electrode renal denervation catheter
por: Templin, Christian, et al.
Publicado: (2013)

Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial
por: Worthley, Stephen G., et al.
Publicado: (2013)

Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Relaxin: Review of Biology and Potential Role in Treating Heart Failure
por: Teichman, Sam L., et al.
Publicado: (2010)

Safety and efficacy of istaroxime in patients with acute heart failure‐related pre‐cardiogenic shock – a multicentre, randomized, double‐blind, placebo‐controlled, parallel group study (SEISMiC)
por: Metra, Marco, et al.
Publicado: (2022)

A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial)
por: Anker, Stefan D., et al.
Publicado: (2015)

Worsening renal function in acute heart failure in the context of diuretic response
por: Emmens, Johanna E., et al.
Publicado: (2021)

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial
por: Metra, Marco, et al.
Publicado: (2022)

Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-Mediated Airway Relaxation
por: Lam, Maggie, et al.
Publicado: (2016)

Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction—a hospital registry-primary care linked cohort (MINAP–GPRD)
por: Boggon, Rachael, et al.
Publicado: (2011)

Variants in the 3′ untranslated region of the KCNQ1-encoded K(v)7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner
por: Amin, Ahmad S., et al.
Publicado: (2012)

A novel clinical method for quantification of regional left ventricular pressure–strain loop area: a non-invasive index of myocardial work
por: Russell, Kristoffer, et al.
Publicado: (2012)

Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation
por: Lauten, Alexander, et al.
Publicado: (2011)

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial
por: Pitt, Bertram, et al.
Publicado: (2011)

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
por: Goto, Shinya, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_jtv3ronitnl96285dair3rugri